Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases

Stratton, Michael R

doi:10.1016/s0140-6736(96)10109-4

Cited by 579BRCA gene mutations in cancerBreast Lesions and CarcinomasBreast Cancer Treatment Studies

Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases

Stratton, Michael R·1997·The Lancet

DOI 10.1016/s0140-6736(96)10109-4

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(96)10109-4

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

BRCA gene mutation might influence response to radiation therapy because tumours in BRCA1/BRCA2 carriers are more sensitive to ionising radiation.
“Several studies suggest that BRCA gene mutation might influence response to radiation therapy because tumours in BRCA1/BRCA2 carriers are more sensitive to ionising radiation [5-12].”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [7]
BRCA2 mutation carriers present tumours with pathologic features similar to those of sporadic tumours.
“BRCA2 mutation carriers, on the contrary, present tumours with pathologic features similar to those of sporadic tumours [2-10].”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [7]

pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up
Elston, C. W., & Ellis, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,181 · see citing works
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069 · see citing works
Untitled work
(1967) · Project Euclid (Cornell University) · Cited by 4,720 · see citing works
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645 · see citing works
Self-citation
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544 · see citing works
Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K. N., Seal, S., Tran, T. D., Averill, D., et al. (1994) · Science · doi:10.1126/science.8091231 · Cited by 1,918 · see citing works
Self-citation
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850 · see citing works
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed · Cited by 1,580 · see citing works
Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S.
Toutenburg, H. (1974) · Biometrische Zeitschrift · doi:10.1002/bimj.19740160814 · Cited by 1,540 · see citing works
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds
Tavtigian, S. V., Simard, J., Rommens, J. M., Couch, F. J., Shattuck-Eidens, D. M., Neuhausen, S. L., Merajver, S. D., Thorlacius, S., Offit, K., Stoppa‐Lyonnet, D., et al. (1996) · Nature Genetics · doi:10.1038/ng0396-333 · Cited by 838 · see citing works
Localization of the gene for Cowden disease to chromosome 10q22–23
Nelen, M. R., Padberg, G. W. A. M., Peeters, E. A. J., Lin, A. Y., van den Helm, B., Frants, R. R., Goulon, V., Goldstein, A. M., van Reen, M. M. M., Eastern, D. F., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-114 · Cited by 667 · see citing works
An Association between the Risk of Cancer and Mutations in the HRAS1 Minisatellite Locus
Krontiris, T. G., Devlin, B., Karp, D. D., Robert, N. J., & RISCH, N. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308193290801 · Cited by 286 · see citing works
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome
Wooster, R., Mangion, J., Eeles, R., Smith, S., Dowsett, M., Averill, D., Barrett-Lee, P., Easton, D. F., Ponder, B. A. J., & Stratton, M. R. (1992) · Nature Genetics · doi:10.1038/ng1092-132 · Cited by 250 · see citing works
Familiality of cancer in Utah.
Cannon‐Albright, L., Thomas, A., Goldgar, D. E., Gholami, K., Rowe, K., Jacobsen, M. D., McWhorter, W. P., & Skolnick, M. H. (1994) · PubMed · Cited by 199 · see citing works
The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis
Lucas, K. G., Brown, A. E., Armstrong, D., Chapman, D. S., & Heller, G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4 · Cited by 174 · see citing works
Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.
Eisinger, F., Stoppa‐Lyonnet, D., Longy, M., Kerangueven, F., Noguchi, T., Bailly, C., Vincent‐Salomon, A., Jacquemier, J. D., Birnbaum, D., & Sobol, H. (1996) · PubMed · Cited by 171 · see citing works
Pathology reporting in breast cancer screening. Royal College of Pathologists Working Group.
(1991) · Journal of Clinical Pathology · doi:10.1136/jcp.44.9.710 · Cited by 130 · see citing works
Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12–21
Porter, D., Cohen, B. B., Wallace, M. R., Smyth, E., Chetty, U., Dixon, J. M., Steel, C. M., & Carter, D. C. (1994) · British journal of surgery · doi:10.1002/bjs.1800811038 · Cited by 122 · see citing works
Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer
Legha, S. S., Benjamin, R. S., Mackay, B., Yap, H. Y., Wallace, S., Ewer, M. S., Blumenschein, G. R., & Freireich, E. J. (1982) · Cancer · doi:10.1002/1097-0142(19820501)49:9 · Cited by 94 · see citing works
Proliferative potential of brain tumors. Analyses with Ki-67 and anti-dna polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts
Shibuya, M., Ito, S., Tetsuro, M. I. W. A., Davis, R. L., Wilson, C. B., & Hoshino, T. (1993) · Cancer · doi:10.1002/1097-0142(19930101)71:1 · Cited by 90 · see citing works
Tubular Carcinoma of the Breast: Association with Multicentricity, Bilaterality, and Family History of Mammary Carcinoma
Lagios, M. D., Rose, M. R., & Margolin, F. R. (1980) · American Journal of Clinical Pathology · doi:10.1093/ajcp/73.1.25 · Cited by 89 · see citing works
Pathology and heredity of breast cancer in younger women.
Marcus, J. N., Watson, P. A., Page, D. L., et al. (1994) · PubMed · Cited by 84 · see citing works
Genetics, biomarkers, and control of breast cancer: A review
Lynch, H. T., Albano, W. A., Heieck, J. J., Mulcahy, G. M., Lynch, J. F., Layton, M. A., & Danes, B. S. (1984) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(84)90087-6 · Cited by 83 · see citing works
Histoprognostic grade in BRCA1-associated breast cancer
Jacquemier, J. D., Eisinger, F., Birnbaum, D., & Sobol, H. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91060-3 · Cited by 63 · see citing works
An Association Between the Risk of Cancer and Mutations in the HRAS1 Minisatellite Locus
Krontiris, T. G., Devlin, B., & Karp, D. D. (1994) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199409000-00031 · Cited by 63 · see citing works
Ultrastructure of Lipoma
Kim, Y. H., & Reiner, L. (1982) · Cancer · doi:10.1002/1097-0142(19820701)50:1 · Cited by 46 · see citing works
Morphologic Types of Breast Cancer-Age, Bilaterality, and Family History
Erdreich, L. S., Asal, N. R., & HOGE, A. F. (1980) · Southern Medical Journal · doi:10.1097/00007611-198001000-00012 · Cited by 34 · see citing works
Histoprognostic grade in tumours from families with hereditary predisposition to breast cancer
Bignon, Y., Fonck, Y., & Chassagne, M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91310-6 · Cited by 28 · see citing works
Histological Assessment of the Prognostic Factors in Female Breast Cancer
Aaltomaa, S. H., Lipponen, P., Eskelinen, M., et al. (2009) · Oncology · doi:10.1159/000227001 · Cited by 16 · see citing works

Flagged first, then by citations

Sorted by citations

Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · see citing works
Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707 · see citing works
Self-citation
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452 · see citing works
Triple‐negative breast cancer: Present challenges and new perspectives
Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.006 · Cited by 299 · see citing works
Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy
Kirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129 · see citing works
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature
Kirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0685-6 · Cited by 102 · see citing works
Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?
Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., Farante, G., Galimberti, V., Luini, A., Veronesi, P., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0638-7 · Cited by 100 · see citing works
Subtypes of familial breast tumours revealed by expression and copy number profiling
kConFab Investigators, Waddell, N., Arnold, J., Cocciardi, S., da Silva, L., Marsh, A., Riley, J., Johnstone, C. N., Orloff, M., Assie, G., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0653-1 · Cited by 99 · see citing works
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
Foulkes, W. D., Chappuis, P. O., Wong, N., Brunet, J.-S., Vesprini, D., Rozen, F., Yuan, Z. Q., Pollak, M. N., Kuperstein, G., Narod, S. A., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008340723974 · Cited by 86 · see citing works
Hereditary breast cancer: From molecular pathology to tailored therapies
Tan, D. S. P., Marchiò, C., & Reis-Filho, J. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.057950 · Cited by 60 · see citing works
Familial breast cancer: an investigation into the outcome of treatment for early stage disease
Eccles, D., Simmonds, P., Goddard, J., Coultas, M., Hodgson, S., Lalloo, F., Evans, G., & Haites, N. (2001) · Familial Cancer · doi:10.1023/a:1013867917101 · Cited by 53 · see citing works
Survival and tumor characteristics of German hereditary breast cancer patients
Hamann, U., & Sinn, H.-P. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006350518190 · Cited by 48 · see citing works
Prognosis and clinical presentation of BRCA2-associated breast cancer
Loman, N., Johannsson, O., Bendahl, P.-O., Dahl, N., Einbeigi, Z., Gerdes, A.-M., Borg, Å., & Olsson, H. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00098-8 · Cited by 46 · see citing works
<i>BRCA1</i> -Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency
Lips, E. H., Debipersad, R. D., Scheerman, C. E., Mulder, L., Sonke, G. S., van der Kolk, L. E., Wesseling, J., Hogervorst, F. B. L., & Nederlof, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0198 · Cited by 22 · see citing works

Tubulolobular invasive breast cancer: A variant of lobular invasive cancer
Fisher, E. R., Gregorio, R. M., Redmond, C. K., et al. (1977) · Human Pathology · doi:10.1016/s0046-8177(77)80096-8 · Cited by 115 · see citing works
Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade?
Rakha, E. A., van Deurzen, C. H. M., Paish, E. C., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.197 · Cited by 55 · see citing works
Abstract 4798: Genomic alterations in ERBB2 define a subset of pleomorphic invasive lobular breast cancer
Hirshfield, K. M., Sanders, R., Feld, H. K., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-4798
Lobular carcinoma in situ and invasive lobular cancer of the breast
Cocquyt, V., & Belle, S. V. (2005) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200502000-00010 · Cited by 47 · see citing works
[Second operation more frequent following breast-conserving treatment for invasive lobular than for invasive non-lobular carcinoma].
de Zeeuw, S., van den Wildenberg, F. A., Strobbe, L. J. A., et al. (2009) · PubMed · Cited by 1 · see citing works

Authors: Stratton, M. R.
Corresponding author: Stratton, Michael R
ORCID: Stratton, Michael R
Venue: The Lancet
Publisher: Elsevier BV
Published: 1997-05
Volume: 349
Issue: 9064
Pages: 1505-1510
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(96)10109-4
OpenAlex: W2160459637
Cited by: 579
References: 30
Citations by year: 2026: 2 · 2025: 6 · 2024: 2 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 10 · 2019: 8 · 2018: 7 · 2017: 10 · 2016: 7 · 2015: 15 · 2014: 15 · 2013: 19 · 2012: 15
FWCI: 23.52
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet (publishedVersion)
Funders: University of Liverpool
KWF Kankerbestrijding
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: hereditary breast cancer, BRCA1 mutation, BRCA2 mutation, breast cancer histopathology, tumor grade, medullary carcinoma, atypical medullary carcinoma, tubular carcinoma, ductal carcinoma in situ, lobular carcinoma in situ, invasive lobular carcinoma, invasive ductal carcinoma, pleomorphism, mitotic count, tubule formation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks